TIDMMEDG TIDMMEDU

RNS Number : 3462P

Medgenics Inc

30 September 2011

Medgenics, Inc.

(the "Company")

Directors' dealings and issue of equity

30 September 2011

Medgenics, Inc. (NYSE Amex: MDGN and London Stock Exchange - AIM: MEDG and MEDU), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, reports that it was notified on 7 September 2011 that on that date Gary Brukardt, a director of the Company, exercised warrants to subscribe for 45,701 common shares of par value U.S. $0.0001 in the Company ("Common Shares"), at an exercise price of $2.49 each, using the cashless exercise mechanism resulting in the issue to him of 16,197 Common Shares. These Common Shares were issued on 28 September 2011.

Additionally, the Company was notified on 22 September 2011 that, on that date, Andrew Pearlman, President, CEO and a director of the Company, transferred warrants to subscribe for 200,000 Common Shares at an exercise price of $2.49 per Common Share ("Warrants") at nil consideration in equal tranches of 50,000 Warrants to each of the following trusts (Andrew Pearlman and Debbie Pearlman are the sole trustees for each trust):

1. Pearlman Family Trust for the benefit of Micah Chaim Pearlman

2. Pearlman Family Trust for the benefit of Adina Rachel Pearlman

3. Pearlman Family Trust for the benefit of Cela Shoshana Pearlman

4. Pearlman Friends and Family Trust

On 26 September 2011, the Company also issued 12,500 Common Shares at $3.76 (calculated with reference to the mid market price of the Common Shares at the close of the previous business day) in consideration for consulting services. It is expected that these Common Shares together with those issued to Gary Brukardt will be admitted to trading on AIM on 7 October 2011.

As of 30 September 2011 and following the above exercise and share issuance (and a further 30,222 Common Shares issued as a result of the exercise of options and warrants which will be admitted under the block listing application of 6 July 2011), the Company has 9,690,117 Common Shares in issue and has approximately 33 per cent. of Common Shares not in public hands and the amended holdings of Gary Brukardt and Andrew Pearlman (including their related parties as defined by the AIM Rules) are as follows:

 
                             % of                                                                   % of 
                           Issued                                                                 Issued 
                 Common     Share                              Expiry     Exercise       Total     Share 
 Name            Shares   Capital   Instrument      Number      Date        Price    interests   Capital 
 
 Andrew L. 
  Pearlman 
  (Director) & 
  related                           Warrants 
  interests(*)   35,375              **            905,190   31/03/2016    $2.49 
                                    Warrants        35,922   31/03/2016   $0.0002 
                                    Options        182,806   31/03/2016    $2.49 
                                    Options         91,403   14/11/2012    $7.35 
                -------  --------  -----------  ----------  -----------  ---------  ----------  -------- 
 Total           35,375      0.4%                1,215,321                           1,250,696     12.9% 
 
 
 Gary Brukardt 
  (Director)     66,077             Options         26,705   14/11/2012    $7.35 
                                    Options         28,571   13/09/2020    $8.19 
                                    Options         12,857   05/01/2021    $6.55 
                -------  --------  -----------  ----------  -----------  ---------  ----------  -------- 
 Total           66,077      0.7%                   68,133                             134,219      1.4%

Notes

(*) Including interests in 94 Common Shares held by family members and 1,719 Common Shares held by ADP Holdings LLC, a company in which Dr. Pearlman is interested

(**) Including warrants over 50,000 Common Shares with an expiry date of 31/03/2016 and an exercise price of $2.49 in each of the Pearlman Family Trust for the benefit of Micah Chaim Pearlman, the Pearlman Family Trust for the benefit of Adina Rachel Pearlman, the Pearlman Family Trust for the benefit of Cela Shoshana Pearlman and the Pearlman Friends and Family Trust.

For further information, contact:

 
 Medgenics, Inc.                        Phone: +972 4 902 8900 
  Dr. Andrew L. Pearlman 
-------------------------------------  ------------------------ 
 Religare Capital Markets (Nominated    Phone: +44 20 7444 0800 
  Adviser) 
  James Pinner 
  Derek Crowhurst 
-------------------------------------  ------------------------ 
 SVS Securities plc (Joint Broker)      Phone: +44 20 7638 5600 
  Ian Callaway 
-------------------------------------  ------------------------ 
 Nomura Code Securities PLC (Joint      Phone: +44 20 7776 1219 
  Broker) 
  Jon Senior 
-------------------------------------  ------------------------ 
 De Facto Communications                Phone: +44 20 7861 3838 
  Mike Wort 
  Anna Dunphy 
-------------------------------------  ------------------------ 
 Lippert/Heilshorn & Associates, Inc.   Phone: +1 212 838 3777 
  (Investment Relations - US) 
  Anne Marie Fields 
-------------------------------------  ------------------------

<ENDS>

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSEALNEDSDFEFF

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Medgenics(Regs) Charts.